logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharma assesses options after phase III disappointment

CEO, Dr Markku Jalkanen, said he and his team was "incredibly disappointed and surprised" by the results, which were at odds with data garnered from an earlier trial

man on a ventilator
Traumakine was used to treat acute respiratory distress syndrome

Faron Pharma Oy (LON:FARN) said its lead drug did not meet its goals for efficacy following the initial read-out from its phase III INTEREST study.

Chief executive Dr Markku Jalkanen said he and the company's R&D team are now "considering how we can advance Traumakine in clinical development".

A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine results in Q2

Traumakine was used to treat acute respiratory distress syndrome (ARDS), a life threatening ailment caused by an inflammation of the lungs that usually coincides with illnesses such as pneumonia or severe flu.  

The trial found the that at 28 days the median number of ventilator-free days for patients on the drug was 10 days, only slightly higher than the 8.5 days for those taking a placebo with no medical benefit.

Meanwhile, the mortality rate after four weeks was 26.4% for those receiving the Faron treatment and 23% for the placebo group.

CEO Jalkanen said he and his team was "incredibly disappointed and surprised" by the results, which were at odds with data garnered from an earlier trial.

"We need to further analyse the data in order to understand how this study differs from our previous positive results with ARDS patients, both in terms of Traumakine's efficacy, and in the unusually low mortality rate observed in the placebo arm," said Jalkanen.  

He said the Faron team was looking forward to the results of a Japanese study of the drug due in the third-quarter, adding that the company will continue with its plans to advance its next asset, Clevegen, a potential cancer treatment.

 

 

Quick facts: Faron Pharmaceuticals Ltd

Price: 427.5 GBX

AIM:FARN
Market: AIM
Market Cap: £200.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine...

Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their £15mln funding aimed at accelerating the development of its two lead products. Jalkanen says the funds will allow them to prepare the way to market for Traumakine, a treatment...

on 21/2/18

2 min read